China-based Immuno Cure BioTech has announced the initiation of a Phase I clinical study for its ICVAX, a therapeutic vaccine against HIV/AIDS, in Shenzhen. This marks a significant step forward in the development of innovative treatments for HIV/AIDS, a condition that affects millions of people globally.
Study Design and Objectives
The randomized, double-blind, placebo-controlled, dose-escalation study is designed to evaluate the safety and immunogenicity of ICVAX in stable HIV/AIDS patients undergoing antiretroviral therapy. The primary goal of the study is to identify an optimal vaccine regimen that is both safe and immunogenic in stable HIV patients, setting the stage for subsequent clinical trials in the future.
ICVAX Development and Collaboration
ICVAX is developed by Immuno Cure in collaboration with the HKU-AIDS Institute. The vaccine aims to induce broadly reactive polyfunctional viral-specific T cells to achieve a functional cure for HIV/AIDS. This collaborative effort leverages the expertise of both Immuno Cure and the HKU-AIDS Institute to develop a vaccine that could significantly improve the lives of HIV/AIDS patients.
Immuno Cure’s Technology Platforms
Immuno Cure is a clinical-stage biotechnology group based in Hong Kong Science Park. The company focuses on the research and development of vaccines and immunotherapies for cancers, inflammatory, and infectious diseases. Its patented PD-1-Enhanced DNA vaccine and Anti-Δ42-PD1 Blocking Antibody technology platforms, both invented by the HKU-AIDS Institute, form the foundation of its innovative product pipeline.
Pipeline and Future Prospects
In addition to ICVAX, Immuno Cure currently has another PD-1-Enhanced DNA vaccine, ICCOV, in preparation for advancement to a Phase II clinical trial for the fight against COVID-19. This pipeline demonstrates Immuno Cure’s commitment to addressing major global health challenges through cutting-edge research and development.-Fineline Info & Tech
